HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Satigrel

structure given in first source

Also Known As:

4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid; E 5510; E-5510; 4-Pentenoic acid, 4-cyano-5,5-bis(4-methoxyphenyl)-

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Monounsaturated Fatty Acids: 676
      - Satigrel: 3

Related Diseases

1.	Intermittent Claudication 12/01/1996 - "Satigrel improved the cutaneous circulation and symptoms of patients with intermittent claudication." 12/01/1996 - "The present study assessed the effect of oral satigrel on cutaneous circulation in patients with intermittent claudication due to arteriosclerosis obliterans. "
2.	Arteriosclerosis Obliterans 01/01/1998 - "Nine patients with arteriosclerosis obliterans receiving grafts were treated with satigrel, and 10 others were enrolled as untreated controls. " 12/01/1996 - "The present study assessed the effect of oral satigrel on cutaneous circulation in patients with intermittent claudication due to arteriosclerosis obliterans. "
3.	Thrombosis (Thrombus) 12/01/1996 - "Satigrel is a new antiplatelet agent which was previously shown to inhibit platelet aggregation and have an anti-thrombotic effect in various animal thrombosis models. "
4.	Ischemia 11/01/1990 - "E-5510, however, showed no ameliorative effect on ischemia-induced myocardial dysfunction, as expressed by the decrease in regional myocardial shortening.(ABSTRACT TRUNCATED AT 250 WORDS)"

Related Drugs and Biologics

1.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)